Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

被引：5

作者：

Stege, Claudia A. M. ^{[1
]}

Nasserinejad, Kazem ^{[2
]}

Levin, Mark-David ^{[3
]}

Thielen, Noortje ^{[4
]}

Klein, Saskia K. ^{[5
]}

Ludwig, Inge ^{[6
]}

Westerman, Matthijs ^{[7
]}

Ypma, Paula F. ^{[8
]}

Bilgin, Yavuz ^{[9
]}

Sohne, Maaike ^{[10
]}

de Waal, Esther ^{[11
]}

van de Donk, Niels W. C. J. ^{[12
]}

Sonneveld, Pieter ^{[13
]}

Zweegman, Sonja ^{[14
]}

机构：

[1] Vrije Univ Amsterdam, Dept Hematol, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[2] Erasmus MC Canc Inst, Rotterdam, Netherlands

[3] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[4] Diakonessenziekenhuis, Dept Internal Med, Utrecht, Netherlands

[5] Meander MC, Amersfoort, Netherlands

[6] Ziekenhuis Bernoven, Dept Hematol, Bernhoven, Netherlands

[7] Noordwest Ziekenhuisgrp, Alkmaar, Netherlands

[8] Haga Hosp, The Hague, Netherlands

[9] Admiraal de Ruijter Hosp, Goes, Netherlands

[10] Antonius Ziekenhuis, Dept Internal Med, Nieuwegein, Netherlands

[11] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[12] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[13] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[14] Univ Amsterdam, Med Ctr, Canc Canc Amsterdam, Dept Hematol, Amsterdam, Netherlands

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114668

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

596

引用

页数：4

共 50 条

[1] Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study
Stege, Claudia A. M.
Nasserinejad, Kazem
van der Spek, Ellen
Van Kampen, Roel J. W.
Sohne, Maaike
Thielen, Noortje
Bilgin, Yavuz
De Waal, Esther G. M.
Ludwig, Inge
Leijs, Maria B. L.
Kentos, Alain
Timmers, Gert Jan
de Heer, Koen
Westerman, Matthijs
Vekemans, Marie Christiane
Durdu-Rayman, Nazik
van der Burg-de Graauw, Nicole C. H. P.
Van de Donk, Niels W. C. J.
Sonneveld, Pieter
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
BLOOD, 2019, 134
[2] Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
Stege, Claudia A. M.
Nasserinejad, Kazem
Van der Spek, Ellen
Bilgin, Yavuz M.
Kentos, Alain
Sohne, Maaike
van Kampen, Roel J. W.
Ludwig, Inge
Thielen, Noortje
Durdu-Rayman, Nazik
de Graauw, Nicole C. H. P.
van de Donk, Niels W. C. J.
de Waal, Esther G. M.
Vekemans, Marie-Christiane
Timmers, Gert Jan
van Der Klift, Marjolein
Soechit, Savita
Geerts, Paul A. F.
Silbermann, Matthijs H.
Oosterveld, Margriet
Nijhof, Inger S.
Sonneveld, Pieter
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) : 2758 - +
[3] Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study
Groen, Kaz
Stege, Claudia A. M.
Nasserinejad, Kazem
de Heer, Koen
Van Kampen, Roel J. W.
Leijs, Maria B. L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka Lung
Ludwig, Inge
Issa, Djamila
Velders, Gerjo A.
Vekemans, Marie-Christiane
van de Donk, Niels W. C. J.
Timmers, Gert-Jan
Sonneveld, Pieter
Seefat, Maarten R.
Croon-de Boer, Fransien
Tick, Lidwine W.
van der Spek, Ellen
De Waal, Esther G. M.
Sohne, Maaike
Ypma, Paula F.
Nijhof, Inger S.
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
BLOOD, 2021, 138
[4] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Kapoor, Prashant
Gertz, Morie A.
Laplant, Betsy
Malave, Gabriella C.
Wolfe, Eric
Muchtar, Eli
Siddiqui, Mustaqeem A.
Gonsalves, Wilson I.
Emanuel, Angie R.
Kourelis, Taxiarchis
Warsame, Rahma
Dingli, David
Buadi, Francis K.
Hayman, Suzanne R.
Leung, Nelson
Hwa, Yi L.
Hobbs, Miriam A.
Fonder, Amie
Dispenzieri, Angela
Lacy, Martha Q.
Rajkumar, S. Vincent
Kumar, Shaji K.
BLOOD, 2019, 134
[5] Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study
Larocca, Alessandra
Corradini, Paolo
Mina, Roberto
Cascavilla, Nicola
Liberati, Anna Marina
Pescosta, Norbert
Petrucci, Maria Teresa
Ciccone, Giovannino
Capra, Andrea
Patriarca, Francesca
Scalabrini, Delia Rota
Innao, Vanessa
Poggiu, Marco
Cea, Michele
Zambello, Renato
Baraldi, Anna
Belotti, Angelo
Cellini, Claudia
Galli, Monica
Grasso, Mariella
Aquino, Sara
Casaluci, Gloria Margiotta
De Sabbata, Giovanni
Ballanti, Stelvio
Offidani, Massimo
Mancuso, Katia
Boccadoro, Mario
Bringhen, Sara
BLOOD, 2019, 134
[6] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O'Donnell, Elizabeth K.
Suman, Vera Jean
Geyer, Susan M.
Nadeem, Omar
Dinner, Shira
Yee, Andrew J.
Laubach, Jacob P.
Mo, Clifton C.
Tuchman, Sascha A.
Donadio, Kristen
Sinclair, Sarah
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[7] Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial
Hulin, Cyrille
Facon, Thierry
Shustik, Chaim
Belch, Andrew
Petrucci, Maria Teresa
Duehrsen, Ulrich
Lu, Jin
Song, Kevin
Rodon, Philippe
Pegourie, Brigitte
Garderet, Laurent
Hunter, Hannah
Azais, Isabelle
Eek, Richard
Macro, Margaret
Dakhil, Shaker
Houck, Vanessa
Chen, Guang
Ervin-Haynes, Annette
Offner, Fritz
BLOOD, 2014, 124 (21)
[8] Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
Groen, Kaz
Stege, Claudia A. M.
Nasserinejad, Kazem
de Heer, Koen
van Kampen, Roel J. W.
Leys, Rineke B. L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka-Lung
Ludwig, Inge
Issa, Djamila E.
Velders, Gerjo A.
Vekemans, Marie-Christiane
Timmers, Gert-Jan
de Boer, Fransien
Tick, Lidwine W.
Verbrugge, Annelies
Buitenhuis, Danny
Cunha, Sonia M.
van der Spek, Ellen
de Waal, Esther G. M.
Sohne, Maaike
Sonneveld, Pieter
Nijhof, Inger S.
Klein, Saskia K.
van der Donk, Niels W. C. J.
Levin, Mark-David
Ypma, Paula F.
Zweegman, Sonja
ECLINICALMEDICINE, 2023, 63
[9] Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
Suzuki, Kenshi
Shinagawa, Atsushi
Uchida, Toshiki
Taniwaki, Masafumi
Hirata, Hirokazu
Ishizawa, Kenichi
Matsue, Kosei
Ogawa, Yoshiaki
Shimizu, Takayuki
Otsuka, Maki
Matsumoto, Morio
Iida, Shinsuke
Terui, Yasuhito
Matsumura, Itaru
Ikeda, Takashi
Takezako, Naoki
Ogaki, Yumi
Midorikawa, Shuichi
Houck, Vanessa
Ervin-Haynes, Annette
Chou, Takaaki
CANCER SCIENCE, 2016, 107 (05) : 653 - 658
[10] A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone ( DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study
Nooka, Ajay K.
Joseph, Nisha S.
Gupta, Vikas A.
Hofmeister, Craig C.
Dhodapkar, Madhav V.
Burton, Bryan J.
Ahmed, Hafsa M.
Linton, Darrian
Cortoos, Annelore
Lin, Thomas S.
Labotka, Richard
Noga, Stephen J.
Kaufman, Jonathan L.
Lonial, Sagar
BLOOD, 2023, 142

← 1 2 3 4 5 →